Mazaheri Z, Tahaghoghi-Hajghorbani S, Baesi K, Ghazvini K, Amel-Jamehdar S, Youssefi M
Mol Biol Res Commun. 2024; 13(3):117-125.
PMID: 38915452
PMC: 11194027.
DOI: 10.22099/mbrc.2024.48729.1895.
Frola C, Aristegui I, Figueroa M, Radusky P, Cardozo N, Zalazar V
PLoS One. 2023; 18(1):e0279996.
PMID: 36662723
PMC: 9858466.
DOI: 10.1371/journal.pone.0279996.
Kozlakidis Z
Front Public Health. 2022; 10:859900.
PMID: 35372203
PMC: 8968083.
DOI: 10.3389/fpubh.2022.859900.
Mavian C, Coman R, Zhang X, Pomeroy S, Ostrov D, Dunn B
J AIDS Clin Res. 2021; 12(5).
PMID: 34950525
PMC: 8694022.
Jin X, Wang Z, Zhang Z, Wu H, Ruan Y, Zhang C
PLoS One. 2021; 16(12):e0259023.
PMID: 34851959
PMC: 8635345.
DOI: 10.1371/journal.pone.0259023.
Drug resistance mutations in protease gene of HIV-1 subtype C infected patient population.
Misbah M, Gupta P, Roy G, Kumar S, Husain M
Virusdisease. 2021; 32(3):480-491.
PMID: 34631975
PMC: 8473514.
DOI: 10.1007/s13337-021-00725-z.
The role of mutations at codons 32, 47, 54, and 90 in HIV-1 protease flap dynamics.
Chordia P, Dewdney T, Keusch B, Kuiper B, Ross K, Kovari I
Discoveries (Craiova). 2020; 2(4):e27.
PMID: 32309558
PMC: 6941557.
DOI: 10.15190/d.2014.19.
Intron-containing RNA from the HIV-1 provirus activates type I interferon and inflammatory cytokines.
McCauley S, Kim K, Nowosielska A, Dauphin A, Yurkovetskiy L, Diehl W
Nat Commun. 2018; 9(1):5305.
PMID: 30546110
PMC: 6294009.
DOI: 10.1038/s41467-018-07753-2.
Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana.
Martin-Odoom A, Brown C, Odoom J, Bonney E, Ntim N, Delgado E
Virol J. 2018; 15(1):143.
PMID: 30223845
PMC: 6142311.
DOI: 10.1186/s12985-018-1051-2.
HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants.
Smith S, Zhao X, Burke Jr T, Hughes S
Antimicrob Agents Chemother. 2018; 62(9).
PMID: 29987149
PMC: 6125528.
DOI: 10.1128/AAC.01035-18.
Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.
Smith S, Zhao X, Burke Jr T, Hughes S
Retrovirology. 2018; 15(1):37.
PMID: 29769116
PMC: 5956922.
DOI: 10.1186/s12977-018-0420-7.
Development of peptide inhibitors of HIV transmission.
Shi S, Nguyen P, Cabral H, Diez-Barroso R, Derry P, Kanahara S
Bioact Mater. 2018; 1(2):109-121.
PMID: 29744399
PMC: 5883972.
DOI: 10.1016/j.bioactmat.2016.09.004.
Recent and Rapid Transmission of HIV Among People Who Inject Drugs in Scotland Revealed Through Phylogenetic Analysis.
Ragonnet-Cronin M, Jackson C, Bradley-Stewart A, Aitken C, McAuley A, Palmateer N
J Infect Dis. 2018; 217(12):1875-1882.
PMID: 29546333
PMC: 6279140.
DOI: 10.1093/infdis/jiy130.
Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
Szubert A, Prendergast A, Spyer M, Musiime V, Musoke P, Bwakura-Dangarembizi M
PLoS Med. 2017; 14(11):e1002432.
PMID: 29136032
PMC: 5685482.
DOI: 10.1371/journal.pmed.1002432.
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.
Gatell J, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P
AIDS. 2017; 31(18):2503-2514.
PMID: 29112070
PMC: 5690310.
DOI: 10.1097/QAD.0000000000001675.
Occurrence of transmitted HIV-1 drug resistance among Drug-naïve pregnant women in selected HIV-care centres in Ghana.
Martin-Odoom A, Adiku T, Delgado E, Lartey M, Ampofo W
Ghana Med J. 2017; 51(1):20-23.
PMID: 28959068
PMC: 5611950.
DOI: 10.4314/gmj.v51i1.4.
Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada.
Rocheleau G, Franco-Villalobos C, Oliveira N, Brumme Z, Rusch M, Shoveller J
PLoS One. 2017; 12(9):e0184848.
PMID: 28937991
PMC: 5609746.
DOI: 10.1371/journal.pone.0184848.
Low levels of viral suppression among refugees and host nationals accessing antiretroviral therapy in a Kenyan refugee camp.
Mendelsohn J, Spiegel P, Grant A, Doraiswamy S, Schilperoord M, Larke N
Confl Health. 2017; 11:11.
PMID: 28572840
PMC: 5450054.
DOI: 10.1186/s13031-017-0111-3.
HIV-1 transmitted drug resistance mutations among antiretroviral therapy-Naïve individuals in Surabaya, Indonesia.
Kotaki T, Khairunisa S, Witaningrum A, Yunifiar M M, Sukartiningrum S, Noor Diansyah M
AIDS Res Ther. 2017; 12:5.
PMID: 28561075
PMC: 4336490.
DOI: 10.1186/s12981-015-0046-y.
Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.
Cahn P, Rolon M, Figueroa M, Gun A, Patterson P, Sued O
J Int AIDS Soc. 2017; 20(1):21678.
PMID: 28537061
PMC: 5515053.
DOI: 10.7448/IAS.20.01.21678.
